Healthcare Industry News: TYRX
News Release - January 8, 2008
TyRx Pharma, Inc. Announces the Appointment of Robert M. (Bob) Mattioli as Vice President, Commercial DevelopmentMONMOUTH, NJ--(Healthcare Sales & Marketing Network)--Jan 8, 2008 -- TYRX Pharma, Inc., a leader in the commercialization of implantable medical-pharmaceutical devices, today announced that it has appointed Robert M. Mattioli as Vice President, Commercial Development. "Bob brings over 30 years' experience in building commercial organizations to TYRX and we are excited to have him join our team," remarked William Edelman, President and CEO for TYRX. Mr. Edelman continued, "Bob's tremendous depth and experience will support our strategy in the implantable medical-pharmaceutical device sector as TYRX moves from the development stage to a full commercial footing."
Mr. Mattioli has more than 30 years of successful sales and marketing experience in the cardiovascular device industry, with specific skills centered on cardiac arrhythmia therapies. He has held key management positions for corporations such as St. Jude Medical, Guidant, Biotronik Inc. and Cordis Corporation. Most recently, as VP Global Sales for Cryocath Technologies Inc., Mr. Mattioli was the principal architect for the successful commercial global adoption of cryoablation technology for cardiac arrhythmia applications. In this role he grew a new emerging technology to a $40M run rate within 4 years of its commercial inception in the USA.
"TYRX Pharma is positioned to be an important leader in the new medical device space defined by pharmaceutical therapies and medical device delivery systems expanding the capabilities of both entities. I am excited to be once again engaged in establishing the clinical and commercial viability of an emerging technology, as I experienced with both the AICD and cryoablation," said Bob.
This notice follows TYRX's October 19th announcement that the paper entitled, "Prevention of Experimental Capsular Contracture in Breast Implants by an Antimicrobial-Impregnated Biodegradable Wrap" was accepted for presentation during the Plastic Surgery 2007 Meeting on October 28, 2007 in Baltimore MD (October 9-12, 2007, Denver, CO).
On October 16th, 2006, TYRX Pharma, Inc. filed a Premarket Application for PIVIT(TM) CRM, an innovative mesh pouch coated with TYRX's proprietary bioresorbable polymer. These polymers contain the antimicrobial agents, rifampin and minocycline, and are designed to enclose a pacemaker or ICD pulse generator when implanted in the body. PIVIT(TM) CRM acts to provide protection from microbial colonization of the pulse generator during surgical implantation. According to a recent study presented during the Heart Rhythm Society 2006 Scientific Sessions (Boston) the University of Pittsburgh Medical Center noted that the 2003 national incident of infection for pacemakers was estimated to be 5.82% and for ICDs 3.71%. Recent market research indicates that more than 500,000 pulse generators are implanted each year.
About TYRX Pharma, Inc.
TYRX Pharma, Inc., an ISO 9001:2000 and ISO 13485:2003 certified medical device manufacturer, commercializes combination medical products utilizing novel biomaterials technology licensed exclusively from Rutgers, The State University of New Jersey. Additionally, TYRX has exclusively licensed from Baylor College of Medicine and The University of Texas M.D. Anderson Cancer Center product patents and associated technologies to address the problem of postsurgical nosocomial infection. TYRX is deploying its capabilities across a broad range of combination products. The combination products sector (products incorporating both a drug & a device component) is expected to be the highest growth segment of the medical products industry and TYRX is positioned to be an innovative applications leader in the space. For more information, please visit www.TYRXpharma.com.
Source: TyRx Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.